Sartorius Aktiengesellschaft logo

Sartorius Aktiengesellschaft(OTC) SOAGY

Market Cap$10.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-35%
5 Year-53%
1 Year+13%
1 Month+6%
$58.21
-0.40%
-0.23Today
Sartorius Aktiengesellschaft last closing stock price
MetricPriceDate
Last closeUSD 58.212026-10-07
Sartorius Aktiengesellschaft stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.67%USD 58.612026-09-30
1 month+5.77%USD 55.042026-09-04
3 month+9.11%USD 53.352026-07-09
Year to date+0.59%USD 57.872025-12-31
1 year+13.44%USD 51.322025-10-07
3 year-12.83%USD 66.782023-10-06
5 year-53.44%USD 125.012021-09-30
Since inception-35.33%USD 90.362020-10-13

Sartorius Aktiengesellschaft Financials at a Glance

Market Cap

$10.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€3.59B

Net Income (TTM)

€196.64M

EPS (TTM)

$0.66

P/E Ratio

88.21

Dividend

$0.17

Beta (Volatility)

0.70 (Low)

Price

$58.21

Volume

5,686

Open

$57.71

Previous Close

$58.21

Daily Range

$57.65 - $58.38

52-Week Range

$46.97 - $62.15

Estimated Earnings Date

Apr 25, 2024

SOAGY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sartorius Aktiengesellschaft

Sartorius AG is a leading global partner for the biopharmaceutical industry, providing innovative solutions for research and production. The company operates through two main divisions: Bioprocess Solutions and Lab Products and Services, focusing on enhancing the efficiency and safety of biopharmaceutical manufacturing.

Products and Services
  • Bioprocess Solutions for biotech medication and vaccine production
  • Lab Products and Services for research and quality control in laboratories
  • Single-use solutions to streamline manufacturing processes
Growth Outlook
  • Revenue of €911.8 million in Q2 2026, showing strong demand
  • Operating income margin of 17.9% indicates effective cost management
  • Continued investment in R&D to drive innovation and market expansion
Financial Highlights
  • Net income of €65.9 million in Q2 2026, reflecting solid profitability
  • Trailing twelve months (TTM) revenue of €3.6 billion, showcasing consistent growth
  • Dividend yield of 0.29%, providing a return to shareholders
Sartorius AG has established itself as a key player in the biopharmaceutical sector, with a focus on innovation and efficiency. The company's recent financial performance highlights its ability to generate substantial revenue and maintain profitability, even in a competitive market. The strong operating income margin suggests effective management of costs, while ongoing investments in research and development position Sartorius for future growth. With a solid dividend yield, the company also offers potential returns for investors. Overall, Sartorius AG presents a compelling opportunity for those interested in the healthcare and biopharmaceutical industries.
AI Generated • Sep 24, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

14,279

CEO

Michael Grosse, PhD

Website

www.sartorius.com

Headquarters

Göttingen, NI 37079, DE

SOAGY Financials

Key Financial Metrics (TTM)

Gross Margin

45.71%

Operating Margin

17.68%

Net Income Margin

4.79%

Return on Equity

6.28%

Return on Capital

8.95%

Return on Assets

1.79%

Earnings Yield

1.13%

Dividend Yield

0.29%

Payout Ratio

29.64%

Stock Overview

Market Cap

$10.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

174.07M

Volume

5.69K

Avg. Volume

5.50K

Financials (TTM)

Gross Profit

€1.64B

Operating Income

€620.17M

EBITDA

€1.05B

Operating Cash Flow

€744.08M

Capital Expenditure

-€437.68M

Free Cash Flow

€306.31M

Cash & ST Invst.

€306.90M

Total Debt

€4.05B

Sartorius Aktiengesellschaft Performance Analysis

Sartorius Aktiengesellschaft annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 4,387,502,4807.6%
20232023-12-31EUR 3,671,144,253-16.3%
20242024-12-31EUR 3,656,871,940-0.4%
20252025-12-31EUR 3,993,021,6479.2%
Sartorius Aktiengesellschaft sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.9%
Q42025-12-319.2%
Q12026-03-31-0.5%
Q22026-06-30-0.2%
Sartorius Aktiengesellschaft annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.0889.1%
20232023-12-31EUR 0.65-68.8%
20242024-12-31EUR 0.26-59.4%
20252025-12-31EUR 0.5192.2%
Sartorius Aktiengesellschaft sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3034.0%
Q42025-12-31-31.7%
Q12026-03-3193.0%
Q22026-06-3014.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€911.80M

+3.1%

Gross Profit

€433.10M

+4.1%

Gross Margin

47.50%

N/A

Market Cap

$10.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$724.45K

N/A

Employees

14,042

N/A

Net Income

€65.90M

+102.8%

EBITDA

€282.10M

+20.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€306.90M

-64.8%

Total Debt

€4.05B

-13.0%

Accounts Receivable

€305.90M

-2.4%

Inventory

€831.90M

+4.3%

Long Term Debt

€3.65B

-10.8%

Short Term Debt

€403.90M

-28.8%

Return on Assets

1.79%

N/A

Return on Invested Capital

7.76%

N/A

Free Cash Flow

€92.10M

+42.1%

Operating Cash Flow

€175.50M

+16.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIOBio-Rad Laboratories, Inc.
$367.92-0.25%
RGENRepligen Corporation
$167.22-4.37%
WSTWest Pharmaceutical Services, Inc.
$366.48-1.65%
LZAGYLonza Group AG
$69.09-0.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$113.12+0.55%
NUNu Holdings
$15.58-0.51%
NVDANvidia
$237.47-0.74%
BULLWebull
$5.89-19.09%

Questions About SOAGY

What is the current price of Sartorius Aktiengesellschaft?

Sartorius Aktiengesellschaft is trading at $58.21 per share.

What is the 52-week range for Sartorius Aktiengesellschaft?

Over the past 52 weeks, Sartorius Aktiengesellschaft has traded between $46.97 and $62.15.

How much debt does Sartorius Aktiengesellschaft have?

As of the most recent reporting period, Sartorius Aktiengesellschaft reported total debt of €4.63B.

How much cash does Sartorius Aktiengesellschaft have on hand?

Sartorius Aktiengesellschaft reported €332.70M in cash and cash equivalents in its most recent financial results.

What is Sartorius Aktiengesellschaft’s dividend yield?

Sartorius Aktiengesellschaft currently has a dividend yield of 0.29%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services